Literature DB >> 22290366

Guidelines for treating depressive illness with antidepressants: A statement from the British Association for Psychopharmacology.

S A Montgomery, P Bebbington, P Cowen, W Deakin, P Freeling, C Hallstrom, C Katona, D King, B Leonard, S Levine, A Phanjoo, M Peet, C Thompson.   

Abstract

Depression is a common illness which affects some 3% of the population per year. At least 25% of those with marked depression do not consult their general practitioner and in half of those who do the illness is not detected. Depression is easy to recognize when four or five of the core symptoms have been present for 2 weeks which often coincides with some occupational and social impairment. The core symptoms are depressed mood, loss of interest or pleasure, loss of energy or fatigue, concentration difficulties, appetite disturbance, sleep disturbance, agitation or retardation, worthlessness or self blame and suicidal thoughts. A diagnosis of depression is made when five of these core symptoms, one of which should be depressed mood or loss of interest or pleasure, have been present for 2 weeks. Four core symptoms are probably sufficient. Response to antidepressants is good in those with more than mild symptoms. When there are only few or very mild depressive symptoms evidence of response to antidepressants is more uncertain. Antidepressants are effective, they are not addictive and do not lose efficacy with prolonged use. The newer antidepressants have fewer side effects than the older tricyclics, they are better tolerated and lead to less withdrawals from treatment. They are less cardiotoxic and are safer in overdose. Antidepressants should be used at full therapeutic doses. Treatment failure is often due to too low a dose being used in general practice. It may be difficult to reach the right dose with the older tricyclics because of side effects. To consolidate response, treatment should be continued for at least 4 months after the patient is apparently well. Stopping the treatment before this is ill-advised as the partially treated depression frequently returns. Most depression is recurrent. Long-term antidepressant treatment is effective in reducing the risk of new episodes of depression and should be continued to keep the patient well.

Entities:  

Year:  1993        PMID: 22290366     DOI: 10.1177/0269881193007001041

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  14 in total

Review 1.  Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: Depression and its treatment.

Authors:  J A Henry; C A Rivas
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

Review 2.  Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 2: Cost-effectiveness analyses.

Authors:  J A Henry; C A Rivas
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

Review 3.  Fluoxetine. A pharmacoeconomic review of its use in depression.

Authors:  M I Wilde; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

4.  Pharmacodynamics of milnacipran in young and elderly volunteers.

Authors:  I Hindmarch; U Rigney; N Stanley; M Briley
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

Review 5.  Epidemiology and relative toxicity of antidepressant drugs in overdose.

Authors:  J A Henry
Journal:  Drug Saf       Date:  1997-06       Impact factor: 5.606

Review 6.  Pharmacotherapy to sustain the fully remitted state.

Authors:  Sidney Kennedy; Roger McIntyre; Angelo Fallu; Raymond Lam
Journal:  J Psychiatry Neurosci       Date:  2002-07       Impact factor: 6.186

7.  Effects of rapid tryptophan depletion on mood and urge to drink in patients with co-morbid major depression and alcohol dependence.

Authors:  Amira Pierucci-Lagha; Richard Feinn; Vania Modesto-Lowe; Robert Swift; Maggie Nellissery; Jonathan Covault; Henry R Kranzler
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

8.  Selective serotonin reuptake inhibitor use in primary care: a 5-year naturalistic study.

Authors:  J Donoghue
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

9.  Protocol for the THREAD (THREshold for AntiDepressants) study: a randomised controlled trial to determine the clinical and cost-effectiveness of antidepressants plus supportive care, versus supportive care alone, for mild to moderate depression in UK general practice.

Authors:  Judy Chatwin; Tony Kendrick
Journal:  BMC Fam Pract       Date:  2007-01-04       Impact factor: 2.497

10.  Quality of care for major depression and its determinants: a multilevel analysis.

Authors:  Arnaud Duhoux; Louise Fournier; Lise Gauvin; Pasquale Roberge
Journal:  BMC Psychiatry       Date:  2012-09-17       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.